GangaGen cultures $5.4M to treat bacterial infections
Biotech firm GangaGen, based in Palo Alto, Calif., brought in $5.4 million in fifth-round funding from ATEL Ventures, Otsuka Pharmaceuticals and ICF Ltd. to develop treatments for bacterial infections. The company specializes in antibiotic-resistant strains of bacteria, like Staphylococcus, in the medical, veterinary and agricultural areas. It currently has a preventative prophylactic and a topical treatment for wounds and burns in the works.
Next Story: LiveRail gets $500K infusion for online video ads
Previous Story: Microsoft goes for The Guild
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.